Canadian Hypertension Education Program: The Science Supporting New 2011 CHEP Recommendations With an Emphasis on Health Advocacy and Knowledge Translation

Canadian Journal of Cardiology

Volumn 27, Issue 4, 2011, Pages 407-414

  Campbell, Norman R C ^a   Poirier, Luc ^b   Tremblay, Guy ^b   Lindsay, Patrice ^c   Reid, Deb ^d   Tobe, Sheldon W ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Canadian Stroke Network   (Canada)

^d Dietitians of Canada   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; THIAZIDE DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN ISCHEMIA; CANADA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMMUNITY CARE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FIBRINOLYTIC THERAPY; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; GOVERNMENT; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ADVOCACY; PATIENT COMPLIANCE; PROFESSIONAL KNOWLEDGE; PROTEINURIA; STROKE; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; CANADA; COMORBIDITY; HEALTH EDUCATION; HUMANS; HYPERTENSION; PATIENT ADVOCACY;

EID: 80052404769     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.03.004     Document Type: Article

References (48)

1. Wilkins K., Campbell N.R., Joffres M.R., et al. Blood pressure in Canadian adults. Health Rep 2010, 21:37-46.
2. Kearney P.M., Whelton M., Reynolds K., Whelton P.K., He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004, 22:11-19.
3. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043-2050.
4. Leonardi-Bee J., Bath P.M.W., Phillips S.J., Sandercock P.A. IST Collaborative Group Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002, 33:1315-1320.
5. Lisk D.R., Grotta J.C., Lamki L.M., et al. Should hypertension be treated after acute stroke?. A randomized controlled trial using single photon emission computed tomography. Eur Heart J 1993, 50:855-862.
6. Anderson C.S., Huang Y., Wang J.G., et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008, 7:391-399.
7. Anderson C.S., Huang Y., Arima H., et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 2010, 41:307-312.
8. Lindsay M.P., Gubitz G., Bayley M., et al. Canadian Best Practice Recommendations for Stroke Care (Update 2010). On behalf of the Canadian Stroke Strategy Best Practices and Standards Writing Group 2010, Canadian Stroke Network, Ottawa, Ontario, Canada.
9. Delcourt C., Huang Y., Wang J., et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). Int J Stroke 2010, 5:110-116.
10. Hackam D.G., Khan N.A., Hemmelgarn B.R., et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2, therapy. Can J Cardiol 2010, 26:249-258.
11. Grossman E., Messerli F.H., Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001, 22:1343-1352.
12. Sipahi I., Debanne S., Rowland D., Simon D.I., Fang J.C. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11:627-636.
13. Campbell N.R., Leiter L.A., Larochelle P., et al. Hypertension in diabetes: a call to action. Can J Cardiol 2009, 25:299-302.
14. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419. Blood Pressure Lowering Treatment Trialists' Collaboration.
15. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
16. Schrier R.W., Estacio R.O., Esler A., et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
17. Cushman W.C., Evans G.W., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585. The ACCORD Study Group.
18. Lewanczuk R. Hypertension as a chronic disease: what can be done at a regional level?. Can J Cardiol 2008, 24:483-484.
19. Thompson A., Campbell N.R., Cloutier L., et al. Tackling the burden of hypertension in Canada: encouraging collaborative care. Can Fam Physician 2008, 54:1659-1662.
20. Carter B.L., Ardery G., Dawson J.D., et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med 2009, 169:1996-2002.
21. Carter B.L., Doucette W.R., Franciscus C.L., et al. Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention. Pharmacotherapy 2010, 30:228-235.
22. Wu J.Y.F., Leung W.Y.S., Chang S., et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 2006, 333:522-527.
23. McLean D.L., McAlister F.A., Johnson J.A., et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). Arch Intern Med 2008, 168:2355-2361.
24. Tobari H., Arimoto T., Shimojo N., et al. Physician-Pharmacist Cooperation Program for Blood Pressure Control in Patients With Hypertension: a randomized-controlled trial. Am J Hypertens 2010, 19.
25. Carter B.L., Rogers M., Daly J., et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med 2009, 169:1748-1755.
26. Waldron C.-A., van der Weijden T., Ludt S., et al. What are effective strategies to communicate cardiovascular risk information to patients?. A systematic review. Patient Educ Counsel 2010, 113.
27. Soureti A., Hurling R., Murray P., et al. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil 2010, 17:519-523.
28. Grover S.A., Lowensteyn I., Joseph L., et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy. Arch Intern Med 2007, 167:2296-2303.
29. D'Agostino R.B., Ramachandran S., Pencina V.M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2007, 117:743-753.
30. Quinn R.R., Hemmelgarn B.R., Padwal R.S., et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I, blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2010, 26:241-248.
31. Campbell N.R.C., Joffres M.R., McKay D.W. Hypertension surveillance in Canada. Minimum standards for assessing blood pressure in surveys. Can J Public Health 2005, 96:217-220.
32. Leenen F.H., Dumais J., McInnis N.H., et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008, 178:1441-1449.
33. Campbell N.R.C., Conradson H.E., Kang J., et al. Automated assessment of blood pressure using BpTRU compared to assessments by a trained technician and a clinic nurse. Blood Press Monit 2005, 10:257-262.
34. Myers MG, Valdivieso M, Chessman M. The relationship between 'guidelines quality' manual blood pressure and automated office blood pressure supports the use of automated devices in routine clinical practice. Poster presentation. Vancouver, Canada, The 23rd Scientific Meeting of the International Society of Hypertension, 2010.
35. Birkett N.J., Donner A.P., Maynard M.D. Assessing hypertension control in the community: the need for follow-up measurements to ensure clinical relevance. CMAJ 1987, 136:595-600.
36. Leenen F.H., Schiffrin E.L. Control rates of hypertension in North America. Hypertension 2010, 56:571-572.
37. McGowan N., Gough K., Maxwell S., et al. How do we use ambulatory measurement of blood pressure in the management of hypertension?. Blood Press Monit 2007, 12:385-386.
38. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45:142-161.
39. O'Brien E., Asmar R., Beilin L., et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005, 23:697-701.
40. Geleijnse J.M., Kok F.J., Grobbee D.E. Impact of dietary and lifestyle factors on the prevalence of hypertension in Western populations. Eur J Public Health 2004, 14:235-239.
41. Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA 2002, 287:1003-1010.
42. Touyz R.M., Campbell N., Logan A., et al. The 2004 Canadian recommendations for the management of hypertension: Part III, lifestyle modifications to prevent and control hypertension. Can J Cardiol 2004, 20:55-59.
43. Interventions on Diet and Physical Activity: What Works: Methodology 2009, World Health Organization, World Health Organization, Geneva, Switzerland.
44. WHO: A Prioritized Research Agenda for Prevention and Control of Noncommunicable Diseases 2010, World Health Organization, World Health Organization, Geneva, Switzerland.
45. Smith E.R. The Canadian heart health strategy and action plan. Can J Cardiol 2009, 25:451-452.
46. 2008-2013 Action Plan for Global Strategy for the Prevention and Control of Noncommunicable Diseases: Prevent and Control Cardiovascular Diseases, Cancers, Chronic Respiratory Diseases and Diabetes 2008, 1-48. World Health Organization, World Health Organization, Geneva, Switzerland.
47. Chockalingam A., Campbell N., Ruddy T., et al. High blood pressure prevention and control: a Canadian National strategy. CVD Prevention 2000, 3:81-93.
48. Karppanen H., Mervaala E. Sodium intake and hypertension. Prog Cardiovasc Dis 2006, 49:59-75.